Dr. Reddy’s Laboratories Ltd (RDY) has released an update.
Dr. Reddy’s Laboratories Ltd. has expanded their healthcare offerings with the European launch of Nerivio®, a drug-free migraine management device, after its successful introduction in India. The USFDA-approved and CE-mark certified wearable device uses Remote Electrical Neuromodulation (REN) to treat migraines and has already benefited over 45,000 patients globally. The company aims to provide relief to migraine sufferers with this non-invasive technology, alongside their comprehensive patient support program ‘M-Free’ to enhance treatment outcomes.
For further insights into RDY stock, check out TipRanks’ Stock Analysis page.
